BABA vs CVNA

The Advanced Deterministic Scorecard reveals a mixed financial profile for Alibaba (BABA), with a weak Piotroski F-Score of 4/9 indicating suboptimal financial health, and no available Altman Z-Score limiting distress risk assessment. While valuation metrics appear favorable relative to peers—especially a Price/Sales of 0.41 and Forward P/E of 19.50—earnings growth is sharply negative (YoY EPS down 71%), and recent quarterly beats have reversed into consistent misses over the last four quarters. Strong insider sentiment and a bullish analyst consensus (strong_buy) contrast with deteriorating profitability and weak technical trends (10/100). The stock trades significantly above the Graham Number ($102.68) and intrinsic value estimate ($51.38), suggesting overvaluation unless growth rebounds materially.

CVNA presents a stark dichotomy between explosive growth and fragile fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company has achieved massive earnings growth (946.7% YoY) and strong liquidity (Current Ratio 4.31), it trades at a severe premium to its Graham Number ($67.9) and Intrinsic Value ($249.87). The current price of $409.08 reflects high growth expectations that are not yet supported by deterministic health metrics or insider conviction. Consequently, the stock is a high-momentum play with significant underlying fundamental risk.